List of Biologics and Biosimilars
Psoriasis
Learn more about available medications by clicking on any of the tabs below:
TNF Blockers
Etanercept (Enbrel®, biosimilars: Erelzi™, Brenzys®)
How Does It Work?
Etanercept is a biologic that targets the overactive immune system in psoriasis. Etanercept works by supressing tumor necrosis factor-alpha (TNFa). Useful in psoriasis and psoriatic arthritis.
How Is It Used?
Etanercept is an injectable medication that is administered subcutaneously. This can be home dosed.
- For plaque psoriasis: 50 mg twice weekly for 3 months, then 50 mg once weekly thereafter
- For psoriatic arthritis: 50 mg once weekly
Side Effects?
The most common side effects of etanercept include temporary pain and redness around the injection site, and an increased risk of infection. To obtain a comprehensive list of all known potential side effects of etanercept, talk your doctor or pharmacist.
Important Considerations?
Some vaccinations, known as live vaccinations, should be avoided while on etanercept. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on etanercept.
Etanercept and other TNF inhibitory medications should be avoided in patients with or who have a close relative with multiple sclerosis. Etanercept should also be avoided in patients with severe heart failure. Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.
Etanercept should be avoided in patients who are immunocompromised or HIV positive.
Interactions?
Some medications that may interact with etanercept include denosumab, echinacea, and trastuzumab. For a complete list of medications that may interact with etanercept and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.
Product Monograph
- Brenzys®: https://pdf.hres.ca/dpd_pm/00065129.PDF
- Enbrel®: https://pdf.hres.ca/dpd_pm/00060454.PDF
- Erelzi™: https://pdf.hres.ca/dpd_pm/00069556.PDF
- Rymti: https://pdf.hres.ca/dpd_pm/00068678.PDF
The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.
This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.
Patient Support Program
Etanercept (Enbrel®): https://www.amgen.ca/products/patient-assistance/
Etanercept biosimilar (Erelzi™): Call 1-844-27XPOSE (1-844-279-7673) for information
Brenzys
Harmony patient support program
Phone 1-866-556-5663
https://rheuminfo.com/docs/physician-tools/patient-support-programs/Brenzys_EN.pdf
To see if this medication is covered under your provincial formulary click here.
| Province | Class | Generic name | Drug Name | Psoriasis | Psoriatic arthritis | GPP | monograph |
|---|---|---|---|---|---|---|---|
| Alberta | Biologics and Biosimilars | Etanercept | Enbrel® | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00060454.PDF | |
| British Columbia | Biologics and Biosimilars | Etanercept | Enbrel® | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00060454.PDF | |
| Manitoba | Biologics and Biosimilars | Etanercept | Enbrel® | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00060454.PDF | |
| New Brunswick | Biologics and Biosimilars | Etanercept | Enbrel® | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00060454.PDF | |
| Newfoundland and Labrador | Biologics and Biosimilars | Etanercept | Enbrel® | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00060454.PDF | |
| NIHB | Biologics and Biosimilars | Etanercept | Enbrel® | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00060454.PDF | |
| Northwest Territories | Biologics and Biosimilars | Etanercept | Enbrel® | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00060454.PDF | |
| Nova Scotia | Biologics and Biosimilars | Etanercept | Enbrel® | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00060454.PDF | |
| Nunavut | Biologics and Biosimilars | Etanercept | Enbrel® | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00060454.PDF | |
| Ontario | Biologics and Biosimilars | Etanercept | Enbrel® | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00065129.PDF | |
| Prince Edward Island | Biologics and Biosimilars | Etanercept | Enbrel® | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00060454.PDF | |
| Quebec | Biologics and Biosimilars | Etanercept | Enbrel® | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00060454.PDF | |
| Saskatchewan | Biologics and Biosimilars | Etanercept | Enbrel® | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00060454.PDF | |
| Yukon | Biologics and Biosimilars | Etanercept | Enbrel® | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00060454.PDF |
Adalimumab (Humira®, biosimilars: Hadlima®, Hyrimoz®, Idacio®, Amgevita®, Hulio®, Yufyma®, Simlandi®))
How Does It Work?
Adalimumab is a biologic that targets the overactive immune system in psoriasis. Adalimumab works by supressing tumor necrosis factor (TNFa). Useful for psoriasis and psoriatic arthritis.
How Is It Used?
Adalimumab is an injectable medication that is administered subcutaneously. This can be home dosed.
- For plaque psoriasis:
80 mg as an initial dose, then 40 mg every other week starting one week after initial dose - For psoriatic arthritis:
40 mg every other week
Side Effects?
The most common side effects of adalimumab include temporary pain and redness around the injection site, headaches, and an increased risk of infection. To obtain a comprehensive list of all known potential side effects of adalimumab, talk your doctor or pharmacist.
Important Considerations?
ome vaccinations, known as live vaccinations, should be avoided while on adalimumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on adalimumab.
Adalimumab and other TNF inhibitory medications should be avoided in patients with or who have a close relative with multiple sclerosis. Adalimumab should also be avoided in patients with severe heart failure. Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.
Interactions?
Some medications that may interact with adalimumab include abatacept (Orencia®), anakinra (Kineret®) and other TNF-blockers such as Enbrel®, Remicade®, Cimzia®, or Simponi®. Adalimumab can potentially affect the speed at which cyclosporine and warfarin are metabolized and their doses may need to be adjusted. For a complete list of medications that may interact with adalimumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.
Product Monograph
- Abrilada: https://pdf.hres.ca/dpd_pm/00068228.PDF
- Amgevita®: https://pdf.hres.ca/dpd_pm/00067468.PDF
- Hadlima®: https://pdf.hres.ca/dpd_pm/00068763.PDF
- Hulio®: https://pdf.hres.ca/dpd_pm/00071858.PDF
- Humira®: https://pdf.hres.ca/dpd_pm/00067414.PDF
- Hyrimoz®: https://pdf.hres.ca/dpd_pm/00073497.PDF
- Idacio®: https://pdf.hres.ca/dpd_pm/00058541.PDF
- Simlandi: https://pdf.hres.ca/dpd_pm/00075380.PDF
- Yuflyma: https://pdf.hres.ca/dpd_pm/00069429.PDF
The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.
This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.
Patient Support Program
AbbVie Care Support Program
https://abbviecare.ca/
Hadlima
Phone 1-866-556-5663 | https://harmonyorganon.ca/hadlima/en/index.html
Hyrimoz
Phone 1-888-6-SANDOZ (726369) | Email support.continum@sandoz.com
Idacio
Idacio KabiCare patient support program
https://kabicare.ca | Phone 1-888-304-2034| Email info@kabicare.ca
Amgevita
Enliven Services:
Phone: 1-877-936-2735 | Email amgevita@oneenliven.ca
www.amgevita.ca
Hulio
hulio.ca
Phone: 1-844-485-4677 | Email hulio@assistprogram.com
To see if this medication is covered under your provincial formulary click here.
| Province | Class | Generic name | Drug Name | Psoriasis | Psoriatic arthritis | GPP | monograph |
|---|---|---|---|---|---|---|---|
| Alberta | Biologics and Biosimilars | Adalimumab | Humira® | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00067414.PDF | |
| British Columbia | Biologics and Biosimilars | Adalimumab | Humira® | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00067414.PDF | |
| Manitoba | Biologics and Biosimilars | Adalimumab | Humira® | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00067414.PDF | |
| New Brunswick | Biologics and Biosimilars | Adalimumab | Humira® | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00067414.PDF | |
| Newfoundland and Labrador | Biologics and Biosimilars | Adalimumab | Humira® | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00067414.PDF | |
| NIHB | Biologics and Biosimilars | Adalimumab | Humira® | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00067414.PDF | |
| Northwest Territories | Biologics and Biosimilars | Adalimumab | Humira® | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00067414.PDF | |
| Nova Scotia | Biologics and Biosimilars | Adalimumab | Humira® | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00067414.PDF | |
| Nunavut | Biologics and Biosimilars | Adalimumab | Humira® | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00067414.PDF | |
| Ontario | Biologics and Biosimilars | Adalimumab | Humira® | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00068228.PDF | |
| Prince Edward Island | Biologics and Biosimilars | Adalimumab | Humira® | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00067414.PDF | |
| Quebec | Biologics and Biosimilars | Adalimumab | Humira® | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00067414.PDF | |
| Saskatchewan | Biologics and Biosimilars | Adalimumab | Humira® | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00067414.PDF | |
| Yukon | Biologics and Biosimilars | Adalimumab | Humira® | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00067414.PDF |
Infliximab (Remicade®, biosimilars: Inflectra®, Renflexis®, Avsola®, Omvyence™, Remsima™)
How Does It Work?
Infliximab is a biologic that targets the overactive immune system in psoriasis. Infliximab works by supressing tumor necrosis factor-alpha (TNFa). Useful for psoriasis and psoriatic arthritis.
How Is It Used?
Infliximab is an injectable medication that is administered intravenously, useful for psoriasis and psoriatic arthritis. Typically this is done in an infusion centre.
- For plaque psoriasis: 5 mg/kg at 0, 2, and 6 weeks, followed by 5 mg/kg every 8 weeks thereafter
- For psoriatic arthritis: 5 mg/kg at 0, 2, and 6 weeks, followed by 5 mg/kg every 8 weeks thereafter
Side Effects?
The most common side effects of infliximab include temporary pain and redness around the infusion site, headaches, nausea, joint pain, and an increased risk of infection. To obtain a comprehensive list of all known potential side effects of infliximab, talk your doctor or pharmacist.
Important Considerations?
Some vaccinations, known as live vaccinations, should be avoided while on infliximab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on infliximab.
Infliximab and other TNF inhibitory medications should be avoided in patients with or who have a close relative with multiple sclerosis. Infliximab should also be avoided in patients with severe heart failure. Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.
Interactions?
Some medications that may interact with infliximab include cyclosporine, echinacea, phenytoin, and warfarin. For a complete list of medications that may interact with infliximab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.
Product Monograph
- Avsola®: https://pdf.hres.ca/dpd_pm/00065940.PDF
- Inflectra®: https://pdf.hres.ca/dpd_pm/00057004.PDF
- Omvyence™: https://pdf.hres.ca/dpd_pm/00068865.PDF
- Remicade®: https://pdf.hres.ca/dpd_pm/00075118.PDF
- Remsima™: https://pdf.hres.ca/dpd_pm/00074581.PDF
- Renflexis®: https://pdf.hres.ca/dpd_pm/00072737.PDF
The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.
This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.
Patient Support Program
Infliximab (Remicade®): https://www.bioadvancemember.ca/en/global/home
Infliximab biosimilar Inflectra®: https://www.pfizer.ca/assistance-programs
Infliximab biosimilar Renflexis®: http://www.merckharmony.ca/
Avsola
Enliven Services
Ph: 1-877-9ENBREL (936-2735) | Email info@oneenliven.ca
www.enbrel.ca; www.avsola.ca
Remsima
CELLTRION CONNECT™ patient support program for Remsima
Interested individuals can find out more about CELLTRION CONNECT™ by visiting www.celltrionconnect.ca/
To see if this medication is covered under your provincial formulary click here.
| Province | Class | Generic name | Drug Name | Psoriasis | Psoriatic arthritis | GPP | monograph |
|---|---|---|---|---|---|---|---|
| Alberta | Biologics and Biosimilars | Infliximab | Remicade® | No | No | https://pdf.hres.ca/dpd_pm/00075118.PDF | |
| British Columbia | Biologics and Biosimilars | Infliximab | Remicade® | No | No | https://pdf.hres.ca/dpd_pm/00075118.PDF | |
| Manitoba | Biologics and Biosimilars | Infliximab | Remicade® | No | No | https://pdf.hres.ca/dpd_pm/00075118.PDF | |
| New Brunswick | Biologics and Biosimilars | Infliximab | Remicade® | No | No | https://pdf.hres.ca/dpd_pm/00075118.PDF | |
| Newfoundland and Labrador | Biologics and Biosimilars | Infliximab | Remicade® | No | No | https://pdf.hres.ca/dpd_pm/00075118.PDF | |
| NIHB | Biologics and Biosimilars | Infliximab | Remicade® | No | No | https://pdf.hres.ca/dpd_pm/00075118.PDF | |
| Northwest Territories | Biologics and Biosimilars | Infliximab | Remicade® | No | No | https://pdf.hres.ca/dpd_pm/00075118.PDF | |
| Nova Scotia | Biologics and Biosimilars | Infliximab | Remicade® | No | No | https://pdf.hres.ca/dpd_pm/00075118.PDF | |
| Nunavut | Biologics and Biosimilars | Infliximab | Remicade® | No | No | https://pdf.hres.ca/dpd_pm/00075118.PDF | |
| Ontario | Biologics and Biosimilars | Infliximab | Remicade® | No | No | https://pdf.hres.ca/dpd_pm/00065940.PDF | |
| Prince Edward Island | Biologics and Biosimilars | Infliximab | Remicade® | No | No | https://pdf.hres.ca/dpd_pm/00075118.PDF | |
| Quebec | Biologics and Biosimilars | Infliximab | Remicade® | No | No | https://pdf.hres.ca/dpd_pm/00075118.PDF | |
| Saskatchewan | Biologics and Biosimilars | Infliximab | Remicade® | No | No | https://pdf.hres.ca/dpd_pm/00075118.PDF | |
| Yukon | Biologics and Biosimilars | Infliximab | Remicade® | No | No | https://pdf.hres.ca/dpd_pm/00075118.PDF |
Certolizumab pegol (Cimzia®)
How Does It Work?
Certolizumab is a biologic that targets the overactive immune system in psoriasis. Certolizumab works by supressing tumor necrosis factor-alpha (TNFa).
Useful in psoriasis and psoriatic arthritis.
How Is It Used?
Certolizumab is an injectable medication that is administered subcutaneously.
- For plaque psoriasis: 400 mg every 2 weeks
- For psoriatic arthritis: 400 mg at weeks 0, 2, and 4, followed by 200 mg every 2 weeks
Side Effects?
The most common side effects of certolizumab include joint pain, and an increased risk of upper respiratory tract infections and urinary tract infections. To obtain a comprehensive list of all known potential side effects of certolizumab, talk your doctor or pharmacist.
Important Considerations?
Some vaccinations, known as live vaccinations, should be avoided while on certolizumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on certolizumab.
Certolizumab should be avoided in patients with moderate to severe heart failure.
Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.
Interactions?
Some medications that may interact with certolizumab include denosumab, echinacea, and trastuzumab. For a complete list of medications that may interact with certolizumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.
Product Monograph
The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.
This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.
Patient Support Program
UCB Cares 1-800-908-5555
To see if this medication is covered under your provincial formulary click here.
| Province | Class | Generic name | Drug Name | Psoriasis | Psoriatic arthritis | GPP | monograph |
|---|---|---|---|---|---|---|---|
| Alberta | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | SA | https://pdf.hres.ca/dpd_pm/00053920.PDF | |
| British Columbia | Biologics and Biosimilars | Certolizumab-pergol | Cimzia® | No | SA | https://pdf.hres.ca/dpd_pm/00053920.PDF | |
| Manitoba | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | Yes – EDS | https://pdf.hres.ca/dpd_pm/00053920.PDF | |
| New Brunswick | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | SA | https://pdf.hres.ca/dpd_pm/00053920.PDF | |
| Newfoundland and Labrador | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | Yes – S/A | https://pdf.hres.ca/dpd_pm/00053920.PDF | |
| NIHB | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | Yes – L/U | https://pdf.hres.ca/dpd_pm/00053920.PDF | |
| Northwest Territories | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | Yes – L/U | https://pdf.hres.ca/dpd_pm/00053920.PDF | |
| Nova Scotia | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | SA | https://pdf.hres.ca/dpd_pm/00053920.PDF | |
| Nunavut | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | Yes – L/U | https://pdf.hres.ca/dpd_pm/00053920.PDF | |
| Ontario | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | Yes – EAP | https://pdf.hres.ca/dpd_pm/00053920.PDF | |
| Prince Edward Island | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | Yes – S/A | https://pdf.hres.ca/dpd_pm/00053920.PDF | |
| Quebec | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | Yes – S/A | https://pdf.hres.ca/dpd_pm/00053920.PDF | |
| Saskatchewan | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | https://pdf.hres.ca/dpd_pm/00053920.PDF | |||
| Yukon | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | Yes – EDS | https://pdf.hres.ca/dpd_pm/00053920.PDF |
IL17 Blockers
Ixekizumab (Taltz®)
How Does It Work?
Ixekizumab is a biologic that targets the overactive immune system in psoriasis. Ixekizumab works by supressing interleukin-17A. Useful for psoriasis and psoriatic arthritis
How Is It Used?
Ixekizumab is an injectable medication that is administered subcutaneously.
- For plaque psoriasis: 160 mg once, followed by 80 mg at weeks 2, 4, 6, 8, 10 and 12, and then 80 mg every 4 weeks
- For psoriatic arthritis: 160 mg once, followed by 80 mg every 4 weeks
Side Effects?
The most common side effects of ixekizumab include temporary pain and redness around the injection site, and an increased risk of infection. To obtain a comprehensive list of all known potential side effects of ixekizumab, talk your doctor or pharmacist.
Important Considerations?
Some vaccinations, known as live vaccinations, should be avoided while on ixekizumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on ixekizumab.
Ixekizumab should be avoided in patients with currently active or previous history of inflammatory bowel disease.
Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.
Interactions?
Some medications that may interact with ixekizumab include denosumab, echinacea, and trastuzumab. For a complete list of medications that may interact with ixekizumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.
Product Monograph
The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.
This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.
Patient Support Program
Call 1-877-219-8908 for information.
To see if this medication is covered under your provincial formulary click here.
| Province | Class | Generic name | Drug Name | Psoriasis | Psoriatic arthritis | GPP | monograph |
|---|---|---|---|---|---|---|---|
| Alberta | Biologics and Biosimilars | Ixekizumab | Taltz® | SA | SA | https://pdf.hres.ca/dpd_pm/00069828.PDF | |
| British Columbia | Biologics and Biosimilars | Ixekizumab | Taltz® | SA | SA | https://pdf.hres.ca/dpd_pm/00069828.PDF | |
| Manitoba | Biologics and Biosimilars | Ixekizumab | Taltz® | SA | SA | https://pdf.hres.ca/dpd_pm/00069828.PDF | |
| New Brunswick | Biologics and Biosimilars | Ixekizumab | Taltz® | SA | SA | https://pdf.hres.ca/dpd_pm/00069828.PDF | |
| Newfoundland and Labrador | Biologics and Biosimilars | Ixekizumab | Taltz® | SA | SA | https://pdf.hres.ca/dpd_pm/00069828.PDF | |
| NIHB | Biologics and Biosimilars | Ixekizumab | Taltz® | SA | SA | https://pdf.hres.ca/dpd_pm/00069828.PDF | |
| Northwest Territories | Biologics and Biosimilars | Ixekizumab | Taltz® | SA | SA | https://pdf.hres.ca/dpd_pm/00069828.PDF | |
| Nova Scotia | Biologics and Biosimilars | Ixekizumab | Taltz | SA | SA | https://pdf.hres.ca/dpd_pm/00069828.PDF | |
| Nunavut | Biologics and Biosimilars | Ixekizumab | Taltz® | SA | SA | https://pdf.hres.ca/dpd_pm/00069828.PDF | |
| Ontario | Biologics and Biosimilars | Ixekizumab | Taltz® | SA | No | https://pdf.hres.ca/dpd_pm/00069828.PDF | |
| Prince Edward Island | Biologics and Biosimilars | Ixekizumab | Taltz® | SA | SA | https://pdf.hres.ca/dpd_pm/00069828.PDF | |
| Quebec | Biologics and Biosimilars | Ixekizumab | Taltz® | SA | SA | https://pdf.hres.ca/dpd_pm/00069828.PDF | |
| Saskatchewan | Biologics and Biosimilars | Ixekizumab | Taltz® | SA | SA | https://pdf.hres.ca/dpd_pm/00069828.PDF | |
| Yukon | Biologics and Biosimilars | Ixekizumab | Taltz® | SA | SA | https://pdf.hres.ca/dpd_pm/00069828.PDF |
Brodalumab(Siliq™)
How Does It Work?
Brodalumab is a biologic that targets the overactive immune system in psoriasis. Brodalumab works by preventing interleukin-17 from causing inflammation.
How is it Used?
Brodalumab is an injectable medication that is administered subcutaneously.
- For plaque psoriasis: 210 mg at weeks 0, 1, and 2, followed by 210 mg once every 2 weeks
Side Effects?
The most common side effect of brodalumab is an increased risk of infection. To obtain a comprehensive list of all known potential side effects of brodalumab, talk your doctor or pharmacist.
Important Considerations?
Some vaccinations, known as live vaccinations, should be avoided while on brodalumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on brodalumab.
Brodalumab should be avoided in patients with Crohn’s disease.
Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.
Interactions?
Some medications that may interact with brodalumab include denosumab, echinacea, and trastuzumab. For a complete list of medications that may interact with brodalumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.
Product Monograph
The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.
This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.
Patient Support Program
Call 1-844-852-6967 for information.
To see if this medication is covered under your provincial formulary click here.
| Province | Class | Generic name | Drug Name | Psoriasis | Psoriatic arthritis | GPP | monograph |
|---|---|---|---|---|---|---|---|
| Alberta | Biologics and Biosimilars | Brodalumab | Siliq™ | Yes – EDS | N/A | https://pdf.hres.ca/dpd_pm/00075300.PDF | |
| British Columbia | Biologics and Biosimilars | Brodalumab | Siliq™ | Yes – EDS | N/A | https://pdf.hres.ca/dpd_pm/00075300.PDF | |
| Manitoba | Biologics and Biosimilars | Brodalumab | Siliq™ | Yes – EDS | N/A | https://pdf.hres.ca/dpd_pm/00075300.PDF | |
| New Brunswick | Biologics and Biosimilars | Brodalumab | Siliq™ | SA | N/A | https://pdf.hres.ca/dpd_pm/00075300.PDF | |
| Newfoundland and Labrador | Biologics and Biosimilars | Brodalumab | Siliq™ | SA | SA | https://pdf.hres.ca/dpd_pm/00075300.PDF | |
| NIHB | Biologics and Biosimilars | Brodalumab | Siliq™ | Yes – L/U | N/A | https://pdf.hres.ca/dpd_pm/00075300.PDF | |
| Northwest Territories | Biologics and Biosimilars | Brodalumab | Siliq™ | Yes – L/U | N/A | https://pdf.hres.ca/dpd_pm/00075300.PDF | |
| Nova Scotia | Biologics and Biosimilars | Brodalumab | Siliq™ | Yes – EDS | N/A | https://pdf.hres.ca/dpd_pm/00075300.PDF | |
| Nunavut | Biologics and Biosimilars | Brodalumab | Siliq™ | Yes – L/U | N/A | https://pdf.hres.ca/dpd_pm/00075300.PDF | |
| Ontario | Biologics and Biosimilars | Brodalumab | Siliq™ | Yes – L/U | N/A | https://pdf.hres.ca/dpd_pm/00075300.PDF | |
| Prince Edward Island | Biologics and Biosimilars | Brodalumab | Siliq™ | Yes – S/A | N/A | https://pdf.hres.ca/dpd_pm/00075300.PDF | |
| Quebec | Biologics and Biosimilars | Brodalumab | Siliq™ | Yes – S/A | N/A | https://pdf.hres.ca/dpd_pm/00075300.PDF | |
| Saskatchewan | Biologics and Biosimilars | Brodalumab | Siliq™ | https://pdf.hres.ca/dpd_pm/00075300.PDF | |||
| Yukon | Biologics and Biosimilars | Brodalumab | Siliq™ | No | N/A | https://pdf.hres.ca/dpd_pm/00075300.PDF |
Secukinumab (Cosentyx®)
How Does It Work?
Secukinumab is a biologic that targets the overactive immune system in psoriasis. Secukinumab works by supressing interleukin-17A. Useful for psoriasis and psoriatic arthritis.
How Is It Used?
Secukinumab is an injectable medication that is administered subcutaneously.
- For plaque psoriasis: 300 mg once weekly at weeks 0, 1, 2, 3, and 4, followed by 300 mg every 4 weeks
- For psoriatic arthritis: For patients not treated previously by a biological agent – 150 mg (or 300 mg for some patients) once weekly at weeks 0, 1, 2, 3, and 4, followed by 150 mg every 4 weeks. For those with previous treatment with a biologic agent – 300 mg once weekly at weeks 0, 1, 2, 3, and 4, followed by 300 mg every 4 weeks.
Side Effects?
The most common side effect of secukinumab is an increased risk of infection. To obtain a comprehensive list of all known potential side effects of secukinumab, talk your doctor or pharmacist.
Important Considerations?
Some vaccinations, known as live vaccinations, should be avoided while on secukinumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on secukinumab.
Secukinumab should be avoided in patients with currently active or previous history of inflammatory bowel disease.
Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.
Interactions?
Some medications that may interact with secukinumab include denosumab, echinacea, and trastuzumab. For a complete list of medications that may interact with secukinumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.
Product Monograph
The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.
This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.
Patient Support Program
https://www.cosentyx.ca/home/plaque-psoriasis/xpose-your-support-network/
To see if this medication is covered under your provincial formulary click here.
| Province | Class | Generic name | Drug Name | Psoriasis | Psoriatic arthritis | GPP | monograph |
|---|---|---|---|---|---|---|---|
| Alberta | Biologics and Biosimilars | Secukinumab | Cosentyx® | SA | SA | https://pdf.hres.ca/dpd_pm/00075631.PDF | |
| British Columbia | Biologics and Biosimilars | Secukinumab | Cosentyx® | SA | SA | https://pdf.hres.ca/dpd_pm/00075631.PDF | |
| Manitoba | Biologics and Biosimilars | Secukinumab | Cosentyx® | SA | SA | https://pdf.hres.ca/dpd_pm/00075631.PDF | |
| New Brunswick | Biologics and Biosimilars | Secukinumab | Cosentyx® | SA | SA | https://pdf.hres.ca/dpd_pm/00075631.PDF | |
| Newfoundland and Labrador | Biologics and Biosimilars | Secukinumab | Cosentyx® | SA | SA | https://pdf.hres.ca/dpd_pm/00075631.PDF | |
| NIHB | Biologics and Biosimilars | Secukinumab | Cosentyx® | SA | SA | https://pdf.hres.ca/dpd_pm/00075631.PDF | |
| Northwest Territories | Biologics and Biosimilars | Secukinumab | Cosentyx® | SA | SA | https://pdf.hres.ca/dpd_pm/00075631.PDF | |
| Nova Scotia | Biologics and Biosimilars | Secukinumab | Cosentyx® | SA | SA | https://pdf.hres.ca/dpd_pm/00075631.PDF | |
| Nunavut | Biologics and Biosimilars | Secukinumab | Cosentyx® | SA | SA | https://pdf.hres.ca/dpd_pm/00075631.PDF | |
| Ontario | Biologics and Biosimilars | Secukinumab | Cosentyx® | SA | No | https://pdf.hres.ca/dpd_pm/00075631.PDF | |
| Prince Edward Island | Biologics and Biosimilars | Secukinumab | Cosentyx® | SA | SA | https://pdf.hres.ca/dpd_pm/00075631.PDF | |
| Quebec | Biologics and Biosimilars | Secukinumab | Cosentyx® | SA | SA | https://pdf.hres.ca/dpd_pm/00075631.PDF | |
| Saskatchewan | Biologics and Biosimilars | Secukinumab | Cosentyx® | SA | SA | https://pdf.hres.ca/dpd_pm/00075631.PDF | |
| Yukon | Biologics and Biosimilars | Secukinumab | Cosentyx® | SA | SA | https://pdf.hres.ca/dpd_pm/00075631.PDF |
Bimekizumab (Bimzelx) – IL-17A and IL-17F
How Does It Work?
Bimekizumab works by inhibiting the inflammatory proteins known as IL-17A and IL-17F. These inflammatory proteins are present in increased levels in psoriasis and by inhibiting them, this medication can help to achieve skin clearance and improvement in psoriasis symptoms.
How Is It Used?
Bimekizumab is an injectable medication that is administered subcutaneously. Patients can self-inject at home.
Bimekizumab is approved for the treatment of psoriasis. The recommended dose is 320mg (given as 2 subcutaneous injections of 160mg each) every 4 weeks for the first 16 weeks and then every 8 weeks thereafter.
If you weigh more than 120 kg, your healthcare professional may decide to continue your injections every 4 weeks from week 16. Follow your doctor’s instructions for optimal dosing.
Bimekizumab is available as a pre-filled syringe or autoinjector.
Side Effects?
The most common side effects of bimekizumab include an increased risk of upper respiratory tract infection. To obtain a comprehensive list of all known potential side effects of bimekizumab, talk to your doctor or pharmacist.
Important Considerations?
Some vaccinations, known as live vaccinations, should be avoided while on bimekizumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is safe to receive while on bimekizumab.
Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.
Bimekizumab is not recommended in patients with inflammatory bowel disease.
Interactions?
For a complete list of medications that may interact with bimekizumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.
Product Monograph
The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.
This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.
Patient Support Program
UCBCares Patient Support Program
1-800-908-5555
www.UCBCares.ca
| Province | Class | Generic name | Drug Name | Psoriasis | Psoriatic arthritis | GPP | monograph |
|---|---|---|---|---|---|---|---|
| Alberta | Biologics and Biosimilars | Bimekizumab | Bimzelx | Yes – EDS | No | https://pdf.hres.ca/dpd_pm/00074908.PDF | |
| British Columbia | Biologics and Biosimilars | bimekizumab | Bimzelx | Yes – EDS | No | https://pdf.hres.ca/dpd_pm/00074908.PDF | |
| Manitoba | Biologics and Biosimilars | Bimekizumab | Bimzelx | Yes - EDS | No | https://pdf.hres.ca/dpd_pm/00074908.PDF | |
| New Brunswick | Biologics and Biosimilars | Bimekizumab | Bimzelx | SA | SA | https://pdf.hres.ca/dpd_pm/00074908.PDF | |
| Newfoundland and Labrador | Biologics and Biosimilars | Bimekizumab | Bimzelx | SA | SA | https://pdf.hres.ca/dpd_pm/00074908.PDF | |
| NIHB | Biologics and Biosimilars | Bimekizumab | Bimzelx | No | No | https://pdf.hres.ca/dpd_pm/00074908.PDF | |
| Northwest Territories | Biologics and Biosimilars | Bimekizumab | Bimzelx | No | No | https://pdf.hres.ca/dpd_pm/00074908.PDF | |
| Nova Scotia | Biologics and Biosimilars | Bimekizumab | Bimzelx | Yes – EDS | No | https://pdf.hres.ca/dpd_pm/00074908.PDF | |
| Nunavut | Biologics and Biosimilars | Bimekizumab | Bimzelx | No | No | https://pdf.hres.ca/dpd_pm/00074908.PDF | |
| Ontario | Biologics and Biosimilars | Bimekizumab | Bimzelx | Yes - L/U | No | https://pdf.hres.ca/dpd_pm/00074908.PDF | |
| Prince Edward Island | Biologics and Biosimilars | Bimekizumab | Bimzelx | Yes – S/A | No | https://pdf.hres.ca/dpd_pm/00074908.PDF | |
| Quebec | Biologics and Biosimilars | Bimekizumab | Bimzelx | Yes – S/A | No | https://pdf.hres.ca/dpd_pm/00074908.PDF | |
| Saskatchewan | Biologics and Biosimilars | Bimekizumab | Bimzelx | https://pdf.hres.ca/dpd_pm/00074908.PDF | |||
| Yukon | Biologics and Biosimilars | Bimekizumab | Bimzelx | No | No | https://pdf.hres.ca/dpd_pm/00074908.PDF |
To see if this medication is covered under your provincial formulary click here.
IL12/23 Blockers
Ustekinumab (Stelara®)
How Does It Work?
Ustekinumab is a biologic that targets the overactive immune system in psoriasis. Ustekinumab works by suppressing interleukin 12 and interleukin 23. Useful for psoriasis and psoriatic arthritis.
How Is It Used?
Ustekinumab is an injectable medication that is administered subcutaneously. Can be home dosed.
- For plaque psoriasis:
≤100 kg: 45 mg at 0 and 4 weeks, and then every 12 weeks thereafter
>100 kg: 90 mg at 0 and 4 weeks, and then every 12 weeks thereafter - For psoriatic arthritis: 45 mg at 0 and 4 weeks, and then every 12 weeks thereafter.
Side Effects?
The most common side effect of ustekinumab is an increased risk of infection. To obtain a comprehensive list of all known potential side effects of ustekinumab, talk your doctor or pharmacist.
Important Considerations?
Some vaccinations, known as live vaccinations, should be avoided while on ustekinumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on ustekinumab.
Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment
Interactions?
Some medications that may interact with ustekinumab include denosumab, echinacea, and trastuzumab. For a complete list of medications that may interact with ustekinumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.
Product Monograph
- Jamteki: https://pdf.hres.ca/dpd_pm/00073286.PDF
- Stelara®: https://pdf.hres.ca/dpd_pm/00073994.PDF
- Wezlana: https://pdf.hres.ca/dpd_pm/00073953.PDF
The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.
This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.
Patient Support Program
https://www.bioadvancemember.ca/en/global/home
To see if this medication is covered under your provincial formulary click here.
| Province | Class | Generic name | Drug Name | Psoriasis | Psoriatic arthritis | GPP | monograph |
|---|---|---|---|---|---|---|---|
| Alberta | Biologics and Biosimilars | Ustekinumab | Stelara® | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00073994.PDF | |
| British Columbia | Biologics and Biosimilars | Ustekinumab | Stelara® | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00073994.PDF | |
| Manitoba | Biologics and Biosimilars | Ustekinumab | Stelara® | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00073994.PDF | |
| New Brunswick | Biologics and Biosimilars | Ustekinumab | Stelara® | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00073994.PDF | |
| Newfoundland and Labrador | Biologics and Biosimilars | Ustekinumab | Stelara® | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00073994.PDF | |
| NIHB | Biologics and Biosimilars | Ustekinumab | Stelara® | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00073994.PDF | |
| Northwest Territories | Biologics and Biosimilars | Ustekinumab | Stelara® | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00073994.PDF | |
| Nova Scotia | Biologics and Biosimilars | Ustekinumab | Stelara® | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00073994.PDF | |
| Nunavut | Biologics and Biosimilars | Ustekinumab | Stelara® | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00073994.PDF | |
| Ontario | Biologics and Biosimilars | Ustekinumab | Stelara® | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00073994.PDF | |
| Prince Edward Island | Biologics and Biosimilars | Ustekinumab | Stelara® | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00073994.PDF | |
| Quebec | Biologics and Biosimilars | Ustekinumab | Stelara® | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00073994.PDF | |
| Saskatchewan | Biologics and Biosimilars | Ustekinumab | Stelara® | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00073994.PDF | |
| Yukon | Biologics and Biosimilars | Ustekinumab | Stelara® | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00073994.PDF |
IL23 Blockers
Risankizumab (Skyrizi™)
How Does It Work?
Risankizumab is a biologic that targets the overactive immune system in psoriasis and psoriatic arthritis. Risankizumab works by supressing interleukin-23A.
How Is It Used?
The recommended dose of SKYRIZI is 150 mg (two 75 mg injections) administered by subcutaneous injection at Week 0, Week 4, and every 12 weeks thereafter.
Side Effects?
The most common side effect of risankizumab is an increased risk of infection. To obtain a comprehensive list of all known potential side effects of risankizumab, talk your doctor or pharmacist.
Important Considerations?
Some vaccinations, known as live vaccinations, should be avoided while on risankizumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on risankizumab.
Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.
Interactions?
N/A.
Product Monograph
The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.
This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.
Patient Support Program
To see if this medication is covered under your provincial formulary click here.
| Province | Class | Generic name | Drug Name | Psoriasis | Psoriatic arthritis | GPP | monograph |
|---|---|---|---|---|---|---|---|
| Alberta | Biologics and Biosimilars | Risankizumab | Skyrizi™ | SA | No | https://pdf.hres.ca/dpd_pm/00075159.PDF | |
| British Columbia | Biologics and Biosimilars | Risankizumab | Skyrizi™ | SA | No | https://pdf.hres.ca/dpd_pm/00075159.PDF | |
| Manitoba | Biologics and Biosimilars | Risankizumab | Skyrizi™ | SA | No | https://pdf.hres.ca/dpd_pm/00075159.PDF | |
| New Brunswick | Biologics and Biosimilars | Risankizumab | Skyrizi™ | SA | No | https://pdf.hres.ca/dpd_pm/00075159.PDF | |
| Newfoundland and Labrador | Biologics and Biosimilars | Risankizumab | Skyrizi™ | SA | No | https://pdf.hres.ca/dpd_pm/00075159.PDF | |
| NIHB | Biologics and Biosimilars | Risankizumab | Skyrizi™ | SA | No | https://pdf.hres.ca/dpd_pm/00075159.PDF | |
| Northwest Territories | Biologics and Biosimilars | Risankizumab | Skyrizi™ | SA | No | https://pdf.hres.ca/dpd_pm/00075159.PDF | |
| Nova Scotia | Biologics and Biosimilars | Risankizumab | Skyrizi™ | SA | No | https://pdf.hres.ca/dpd_pm/00075159.PDF | |
| Nunavut | Biologics and Biosimilars | Risankizumab | Skyrizi™ | SA | No | https://pdf.hres.ca/dpd_pm/00075159.PDF | |
| Ontario | Biologics and Biosimilars | Risankizumab | Skyrizi™ | SA | No | https://pdf.hres.ca/dpd_pm/00075159.PDF | |
| Prince Edward Island | Biologics and Biosimilars | Risankizumab | Skyrizi™ | SA | No | https://pdf.hres.ca/dpd_pm/00075159.PDF | |
| Quebec | Biologics and Biosimilars | Risankizumab | Skyrizi™ | SA | No | https://pdf.hres.ca/dpd_pm/00075159.PDF | |
| Saskatchewan | Biologics and Biosimilars | Risankizumab | Skyrizi™ | SA | No | https://pdf.hres.ca/dpd_pm/00075159.PDF | |
| Yukon | Biologics and Biosimilars | Risankizumab | Skyrizi™ | SA | No | https://pdf.hres.ca/dpd_pm/00075159.PDF |
Guselkumab (TREMFYA®)
How Does It Work?
Guselkumab is a biologic that targets the overactive immune system in psoriasis. Guselkumab works by neutralizing interleukin-23.
How Is It Used?
Guselkumab is an injectable medication that is administered subcutaneously by injection. Guselkumab can be used alone or in combination with a conventional disease-modifying antirheumatic drug (cDMARD) such as methotrexate.
- For plaque psoriasis: 100 mg at weeks 0 and 4, and then every 8 weeks thereafter
- For psoriatic arthritis: 100 mg at weeks 0 and 4, and then every 8 weeks thereafter
Side Effects?
The most common side effect of guselkumab is an increased risk of respiratory tract infections. To obtain a comprehensive list of all known potential side effects of guselkumab, talk your doctor or pharmacist.
Important Considerations?
Some vaccinations, known as live vaccinations, should be avoided while on guselkumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on guselkumab.
Patients should be screened for tuberculosis and infections prior to treatment.
Do not use TREMFYA®/TREMFYA One-Press™ if you are allergic to guselkumab or any of the ingredients in TREMFYA®/TREMFYA OnePress™.
If you think you are allergic, ask your healthcare professional for advice before using TREMFYA®/TREMFYA One-Press™.
Interactions?
For a complete list of medications that may interact with guselkumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.
Product Monograph
The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.
This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.
Patient Support Program
To see if this medication is covered under your provincial formulary click here.
| Province | Class | Generic name | Drug Name | Psoriasis | Psoriatic arthritis | GPP | monograph |
|---|---|---|---|---|---|---|---|
| Alberta | Biologics and Biosimilars | Guselkumab | Tremfya® | Yes – EDS | Yes – EDS | https://pdf.hres.ca/dpd_pm/00075605.PDF | |
| British Columbia | Biologics and Biosimilars | guselkumab | Tremfya® | Yes – EDS | Yes – EDS | https://pdf.hres.ca/dpd_pm/00075605.PDF | |
| Manitoba | Biologics and Biosimilars | Guselkumab | Tremfya® | Yes - EDS | Yes - EDS | https://pdf.hres.ca/dpd_pm/00075605.PDF | |
| New Brunswick | Biologics and Biosimilars | Guselkumab | Tremfya® | Yes – S/A | Yes – S/A | https://pdf.hres.ca/dpd_pm/00075605.PDF | |
| Newfoundland and Labrador | Biologics and Biosimilars | Guselkumab | Tremfya® | SA | SA | https://pdf.hres.ca/dpd_pm/00075605.PDF | |
| NIHB | Biologics and Biosimilars | Guselkumab | Tremfya® | Yes - L/U | Yes - L/U | https://pdf.hres.ca/dpd_pm/00075605.PDF | |
| Northwest Territories | Biologics and Biosimilars | Guselkumab | Tremfya® | Yes - L/U | Yes - L/U | https://pdf.hres.ca/dpd_pm/00075605.PDF | |
| Nova Scotia | Biologics and Biosimilars | Guselkumab | Tremfya® | Yes – EDS | Yes – EDS | https://pdf.hres.ca/dpd_pm/00075605.PDF | |
| Nunavut | Biologics and Biosimilars | Guselkumab | Tremfya® | Yes - L/U | Yes - L/U | https://pdf.hres.ca/dpd_pm/00075605.PDF | |
| Ontario | Biologics and Biosimilars | Guselkumab | Tremfya® | Yes - L/U | Yes - EAP | https://pdf.hres.ca/dpd_pm/00075605.PDF | |
| Prince Edward Island | Biologics and Biosimilars | Guselkumab | Tremfya® | Yes – S/A | Yes – S/A | https://pdf.hres.ca/dpd_pm/00075605.PDF | |
| Quebec | Biologics and Biosimilars | Guselkumab | Tremfya® | Yes - S/A | No | https://pdf.hres.ca/dpd_pm/00075605.PDF | |
| Saskatchewan | Biologics and Biosimilars | Guselkumab | Tremfya® | Yes - EDS | Yes - EDS | https://pdf.hres.ca/dpd_pm/00075605.PDF | |
| Yukon | Biologics and Biosimilars | Guselkumab | Tremfya® | No | No | https://pdf.hres.ca/dpd_pm/00075605.PDF |
Tildrakizumab (Ilumya®)
How Does It Work?
ILUMYA® acts on specific molecular signals used by the immune system to decrease the immune system’s overactivity that can contribute to plaque psoriasis.
How Is It Used?
ILUMYA® is a drug taken by injection often in 12-week intervals following loading doses.
Side Effects?
Side effects of ILUMYA® can include diarrhea, skin irritation and muscle pain at the injection site, fatigue, increased risk of infection, joint pain, and headaches. To obtain a comprehensive list of all potential side effects, talk to your doctor or pharmacist.
Important Considerations?
Not applicable
Interactions?
Live vaccines cannot be taken while on ILUMYA®. Talk to your doctor before being vaccinated to confirm it is safe to do so while on ILUMYA®. ILUMYA®may also interact with dextromethorphan. Ask your doctor or pharmacist if you are concerned about a drug interaction.
Product Monograph
The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.
This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.
Patient Support Program
Phone: 1-844-561-1259 (Canada)
Available Monday-Friday, 8.00 AM – 8.00 PM Est
Website: ilumya.ca
Email: ilumya@bayshore.ca
To see if this medication is covered under your provincial formulary click here.
| Province | Class | Generic name | Drug Name | Psoriasis | Psoriatic arthritis | GPP | monograph |
|---|---|---|---|---|---|---|---|
| Alberta | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | SA | N/A | https://pdf.hres.ca/dpd_pm/00064464.PDF | |
| British Columbia | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | No | N/A | https://pdf.hres.ca/dpd_pm/00064464.PDF | |
| Manitoba | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | SA | N/A | https://pdf.hres.ca/dpd_pm/00064464.PDF | |
| New Brunswick | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | SA | N/A | https://pdf.hres.ca/dpd_pm/00064464.PDF | |
| Newfoundland and Labrador | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | SA | N/A | https://pdf.hres.ca/dpd_pm/00064464.PDF | |
| NIHB | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | SA | N/A | https://pdf.hres.ca/dpd_pm/00064464.PDF | |
| Northwest Territories | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | SA | N/A | https://pdf.hres.ca/dpd_pm/00064464.PDF | |
| Nova Scotia | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | SA | N/A | https://pdf.hres.ca/dpd_pm/00064464.PDF | |
| Nunavut | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | SA | N/A | https://pdf.hres.ca/dpd_pm/00064464.PDF | |
| Ontario | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | SA | N/A | https://pdf.hres.ca/dpd_pm/00064464.PDF | |
| Prince Edward Island | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | SA | N/A | https://pdf.hres.ca/dpd_pm/00064464.PDF | |
| Quebec | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | SA | N/A | https://pdf.hres.ca/dpd_pm/00064464.PDF | |
| Saskatchewan | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | SA | N/A | https://pdf.hres.ca/dpd_pm/00064464.PDF | |
| Yukon | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | No | N/A | https://pdf.hres.ca/dpd_pm/00064464.PDF |
IL36 Blocker (generalized pustular psoriasis flares)
Spesolimab (SPEVIGO®)
How Does It Work?
SPEVIGO (spesolimab for injection) inhibits the inflammatory signaling pathway of interleukin 36 (IL-36), and is indicated for the treatment of flares in adult patients with generalized pustular psoriasis (GPP).
How Is It Used?
Treatment with SPEVIGO (spesolimab for injection) should be initiated by physicians experienced in the management of patients with inflammatory skin diseases.
The recommended dose of SPEVIGO (spesolimab for injection) is a single dose of 900 mg (2 x 450 mg/7.5 ml vials) administered as an intravenous infusion. If flare symptoms persist, an additional 900 mg dose may be administered 1 week after the initial dose.
Side Effects?
The most common side effects of SPEVIGO (spesolimab for injection) include fatigue/weakness, nausea and vomiting, headache, itching or itchy bumps, a collection of blood under the skin at the infusion site or bruising, and urinary tract infection. To obtain a comprehensive list of all known potential side effects of roflumilast, talk to your doctor or pharmacist.
Important Considerations?
SPEVIGO (spesolimab for injection) is contraindicated in patients with severe or life-threatening hypersensitivity to this drug or to any ingredients in the formulation, including any non-medicinal ingredients, or components of the container.
Interactions?
No formal drug-drug interaction studies were conducted with SPEVIGO (spesolimab for injection). For a complete list of medications that may interact with SPEVIGO (spesolimab for injection) and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.
Product Monograph
- https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102523
- https://pdf.hres.ca/dpd_pm/00070263.PDF
The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.
This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.
Patient Support Program
headstartGO@supportprogram.com
Call toll-free: 1-833-773-4746
MedInfo can be accessed by health care providers for possible inquiries (1-800-263-5103 x84643, zrburmedinfo@boehringer-ingelheim.com).
To see if this medication is covered under your provincial formulary click here.
| Province | Class | Generic name | Drug Name | Psoriasis | Psoriatic arthritis | GPP | monograph |
|---|---|---|---|---|---|---|---|
| Alberta | Biologics and Biosimilars | spesolimab | Spevigo | N/A | N/A | No | |
| British Columbia | Biologics and Biosimilars | spesolimab | Spevigo | N/A | No | No | |
| Manitoba | Biologics and Biosimilars | spesolimab | Spevigo | N/A | N/A | No | |
| New Brunswick | Biologics and Biosimilars | spesolimab | Spevigo | No | No | No | |
| Newfoundland and Labrador | Biologics and Biosimilars | Spesolimab | Spevigo | N/A | N/A | No | |
| NIHB | Biologics and Biosimilars | Spesolimab | Spevigo | N/A | N/A | No | |
| Northwest Territories | Biologics and Biosimilars | Spesolimab | Spevigo | N/A | N/A | No | https://pdf.hres.ca/dpd_pm/00041695.PDF |
| Nova Scotia | Biologics and Biosimilars | spesolimab | Spevigo | N/A | N/A | No | |
| Nunavut | Biologics and Biosimilars | Spesolimab | Spevigo | N/A | N/A | No | https://pdf.hres.ca/dpd_pm/00041695.PDF |
| Ontario | Biologics and Biosimilars | spesolimab | Spevigo | N/A | N/A | No | |
| Prince Edward Island | Biologics and Biosimilars | spesolimab | Spevigo | N/A | N/A | No | |
| Quebec | Biologics and Biosimilars | Spesolimab | Spevigo | N/A | N/A | No | |
| Saskatchewan | Biologics and Biosimilars | Spesolimab | Spevigo | N/A | N/A | No | |
| Yukon | Biologics and Biosimilars | Spesolimab | Spevigo | N/A | N/A | No |